Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections

Vaxxel develops the first intranasal live attenuated and multivalent viral vaccine against HMPV and HRSV for paediatric and elderly indications from an innovative HMPV-derived vaccine platform. Discover more in depth about our platform by visiting our website. 

Pneumovirus infections

poumon_ico

Unmet medical need

There are today no licensed vaccine available against hMPV or hRSV (including 46 million children) from these acute respiratory tract infections (ARTIs), causing mild symptoms to severe pathologies, requiring hospitalizations due to bronchiolitis and pneumonia (US and EU, 2018). Efficacious and safe vaccines against pneumovirus infections would have widespread benefits for public health, alleviating the medical and socio-economic burden of ARTIs.

Significant morbidity in children and the elderly

HMPV and HRSV are two major etiologic viral agents of ARTIs in infants below 5 years old and in older adults above 65 years old. In these at-risk populations, these infections can unfortunately result in the death of infected patients.

Science / Technology

Vaxxel R&D program to address the global need in vaccine against pneumoviruses is based on two proprietary technologies :

metavac

Metavac® Vaccine platform

From its expertise in virology, Vaxxel developed a proprietary live-attenuated viral platform based on an engineered recombinant HMPV strain. This proprietary Metavac® platform is versatile by modifying its genome in order to express additional viral antigens of interest, such as the F antigen of HRSV.

bioreacteur

Bioproduction platform

Vaxxel acquired from Transgene the DuckCelt®-T17 avian cell line, permissive to several viruses, including pneumoviruses and producing high yields of Metavac®-based vaccine candidates, while preserving its immunogenic properties. This cell line growing in suspension and serum-free conditions presents suitable characteristics for industrial scalable production in bioreactor.

Science / Technology

Vaxxel R&D program to address the global need in vaccine against pneumoviruses is based on two proprietary technologies :

metavac

Metavac® Vaccine platform

From its expertise in virology, Vaxxel developed a proprietary live-attenuated viral platform based on an engineered recombinant HMPV strain. This proprietary Metavac® platform is versatile by modifying its genome in order to express additional viral antigens of interest, such as the F antigen of HRSV.

bioreacteur

Bioproduction platform

Vaxxel acquired from Transgene the DuckCelt®-T17 avian cell line, permissive to several viruses, including pneumoviruses and producing high yields of Metavac®-based vaccine candidates, while preserving its immunogenic properties. This cell line growing in suspension and serum-free conditions presents suitable characteristics for industrial scalable production in bioreactor.

Roadmap

Our team

Denis Cavert

CEO Co-founder

Dr. Manuel Rosa-Calatrava

Scientific Co-founder

Pr. Guy Boivin

Clinical dev Co-founder

Dr. Julia Dubois

Project manager Co-founder

Dr. Marie-Eve Hamelin

Scientific Co-Founder

Contact us

Invalid Email
Please check the captcha to verify you are not a robot.
greenlogo4

Vaxxel SAS

43, Boulevard du 11 Novembre 1918,

L’Atrium | 69100 Villeurbanne | France

Get in touch

contact@vaxxel.fr

Follow us

Vaxxel © 2020 - All rights reserved